HC Wainwright Reduces Earnings Estimates for Zenas BioPharma

Key Points

• HC Wainwright has lowered earnings estimates for Zenas BioPharma, projecting a Q3 2025 EPS of ($1.08), down from a previous estimate of ($0.93).
• The company reported its latest earnings on August 12, missing the consensus estimate, with an EPS of ($1.25).
• Despite this, HC Wainwright maintains a "Buy" rating for the stock with a price target of $30.00.

Zenas BioPharma, Inc. (NASDAQ:ZBIO - Free Report) - Equities research analysts at HC Wainwright lowered their Q3 2025 earnings per share (EPS) estimates for shares of Zenas BioPharma in a research note issued to investors on Wednesday, August 13th. HC Wainwright analyst M. Caufield now expects that the company will earn ($1.08) per share for the quarter, down from their previous forecast of ($0.93). HC Wainwright currently has a "Buy" rating and a $30.00 target price on the stock. HC Wainwright also issued estimates for Zenas BioPharma's Q4 2025 earnings at ($1.03) EPS, FY2025 earnings at ($4.17) EPS, FY2026 earnings at ($3.69) EPS, FY2027 earnings at ($3.41) EPS, FY2028 earnings at ($2.85) EPS and FY2029 earnings at ($1.87) EPS.

Zenas BioPharma (NASDAQ:ZBIO - Get Free Report) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($1.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.02) by ($0.23).

Other analysts have also recently issued reports about the company. Wedbush reaffirmed an "outperform" rating and set a $35.00 price objective on shares of Zenas BioPharma in a report on Thursday, May 15th. Wall Street Zen downgraded Zenas BioPharma from a "hold" rating to a "sell" rating in a research report on Saturday. Three investment analysts have rated the stock with a Buy rating, According to MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $36.67.

Zenas BioPharma Trading Down 8.3%

Shares of ZBIO traded down $1.43 during mid-day trading on Friday, hitting $15.85. 252,175 shares of the stock were exchanged, compared to its average volume of 181,004. The stock has a market cap of $667.44 million and a P/E ratio of -4.46. Zenas BioPharma has a 52-week low of $5.83 and a 52-week high of $26.25. The stock has a 50-day simple moving average of $12.85.

Hedge Funds Weigh In On Zenas BioPharma

Hedge funds have recently bought and sold shares of the business. New York State Common Retirement Fund bought a new position in shares of Zenas BioPharma during the 1st quarter worth $49,000. PNC Financial Services Group Inc. grew its position in shares of Zenas BioPharma by 41.2% during the 2nd quarter. PNC Financial Services Group Inc. now owns 9,179 shares of the company's stock worth $89,000 after buying an additional 2,679 shares in the last quarter. Sei Investments Co. bought a new position in shares of Zenas BioPharma during the 2nd quarter worth $118,000. Intech Investment Management LLC grew its position in shares of Zenas BioPharma by 13.9% during the 2nd quarter. Intech Investment Management LLC now owns 13,206 shares of the company's stock worth $128,000 after buying an additional 1,607 shares in the last quarter. Finally, Bank of America Corp DE grew its position in shares of Zenas BioPharma by 32.3% during the 2nd quarter. Bank of America Corp DE now owns 13,991 shares of the company's stock worth $136,000 after buying an additional 3,412 shares in the last quarter.

About Zenas BioPharma

Zenas BioPharma, Inc is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.